Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Embecta (EMBC) stock in plain English

Free brief · no signupStart here
EMBCPublished Nov 15, 2026
Embecta Corp
Healthcare · Medical Instruments & Supplies
Manufactures and distributes pen needles, insulin syringes, and safety injection devices for people managing diabetes.
Assets:
Holdrege manufacturing hubworld's largest dedicated pen needle production facility in Nebraska
8 billion units yearlyannual production capacity across plants in the US, Ireland, and China
Becton Dickinson licenseexclusive rights to use the BD Ultra-Fine brand on injection products
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

60
OPS ScoreOperating finances
Latest quote
+1.64%$6.19
$350.73M
4.2×
$1.03B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was EMBC. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Embecta (EMBC) do?

Embecta Corp (EMBC) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Manufactures and distributes pen needles, insulin syringes, and safety injection devices for people managing diabetes. Embecta produces nearly eight billion injection devices annually as the primary supplier of insulin delivery. It is worth $350.73M on the market and sold $1.03B over the last year.

Market cap
$350.73M
P/E ratio
4.2×
Annual sales
$1.03B
Sector
Healthcare
Industry
Medical Instruments & Supplies
Brief updated
Nov 15, 2026

Brands and businesses behind EMBC

  • BD Ultra-Fine: Pen needles and syringes licensed from BD generate the core recurring consumable revenue across global retail pharmacies.
  • BD Micro-Fine: European and international consumer injection brand generating steady consumable revenue through regional medical supply distribution.

EMBC’s flags, in plain English

Each flag is a number from Embecta’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Bargain or Trap?

Priced at 4.2 times its yearly profit, on the cheap side. The stock trades cheaper than it usually does. A low price can hide a real problem, so read the risks.

Cheap on Cash Flow

Priced at 2.1 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Wide Gross Margin

Gross margin of 59.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Growth Cooling

Sales growth slowed to -0.1% a year over 5 years. Sales are growing more slowly than before, which makes the current share price harder to justify.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about EMBC

How big is Embecta?

Embecta’s market cap is $350.73M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.03B: what customers paid the company over the last year, before any costs.

What is EMBC’s P/E ratio?

EMBC’s P/E ratio is 4.2×. Investors pay about 4.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with EMBC?

A heavy reliance on single-use insulin needles leaves the business vulnerable to patients switching to oral GLP-1 medications and automated insulin pumps. That is one risk on Embecta’s card. Its first risk flag is Growth Cooling, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Embecta’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. EMBC’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card